RESUMO
Objective Observing the clinical effect of Ligustrazine Phosphate Tablets combined with percutaneous intratumoral injection of lipiodol THP on advanced hepa-tocellular carcinoma.Methods83 patients with advanced hepatocellular carcinoma from January 2012 to September 2014 were analyzed.Double-blind, randomized method All patients were divided into the control group 41 cases and observation group 42 cases.The control group were treatedwith percutaneous transhepatic intratumoral injection of lipiodol THP, the observation groupwere given Ligustrazine Phosphate Tablets combined with percutaneous intratumoral injection of lipiodol THP to treat.After treatment, the two groups of patients with treatment efficacy, adverse reactions and Karnofsky and prothrombin time were analyzed.ResultsAftertreatment, the efficacy of the two groups of patients were compared, the results showed that patients in the observation group total effective rate of the control group (χ2=4.034),the difference was statistically significant (P<0.05);two groups adverse reactions in patients after treatment were compared, liver pain, blood toxicity, fever, gastrointestinal reactions similar proportion of patients, the difference was not statistically significant;Theproportion of patients in the observation group AFP<8.1ng/mL was significantly higher (χ2=4.338), the difference was statistically significant (P<0.05);patients were observed after treatment Karnofsky score was significantly higher, the difference was statistically significant (t=7.141, P<0.05);after two groups of patients were compared prothrombin time, the difference was not statistically significant.ConclusionHepatic arterial chemoembolization and percutaneous intratumoral injection of THP lipiodol emulsion on the basis of the combination of Ligustrazine Phosphate Tablets can effectively improve the efficacy of treatment, and has good security, which is a safe and effective methods of treatment should be to promote and use in clinical.
RESUMO
A 74-year-old man presented with a progressively worsening pain in sacrum and was diagnosed to have a sacral chordoma by biopsy in May, 2004. Percutaneous intratumoral injection with lipiodol-pingyangmycin suspension (LPS) was carried out under image guidance and repeated when the pain in sacrum recurred and the tumor increased. During a 6-year follow-up period, three sessions of this treatment were executed. CT imaging and Karnofsky Performance Score were used to evaluate the size of tumor and quality of life, respectively. The patient was free of pain after each procedure and had a high quality of life with a Karnofsky Performance Score above 80 points. The tumor lesion in sacral area was effectively controlled. No complications were observed. Percutaneous intratumoral injection with LPS under image guidance may be an effective and safe alternative for the patients with sacral chordoma.